The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 28, No. 1, pp. 105-111.
© 1994 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cimino, M.
Right arrow Articles by Moser, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cimino, M.
Right arrow Articles by Moser, J.

Research Articles

Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients

MA Cimino, CM Rotstein, and JE Moser

OBJECTIVE: To describe the economic benefits of a quality improvement effort directed at optimizing clinical outcome. DESIGN: A before-after observational design was used to evaluate the cost-effectiveness of a consensus approach to antimicrobial therapy. SETTING: The evaluation was conducted at a cancer research hospital. PATIENTS: Oncology patients requiring parenteral antibiotic therapy were consecutively observed. MAIN OUTCOME MEASURES: Outcome (clinical and microbiologic response), safety, and cost of therapy were assessed during a baseline period and compared to a period during which the consensus approach was used. INTERVENTIONS: The influence of a designated individual, in this case a clinical pharmacist, responsible for promotion of the consensus approach was explored. RESULTS: The consensus approach in combination with the promotional efforts of the clinical pharmacist was associated with a 13 percent increase in overall clinical response and a reduction of pathogen persistence from 22 to 11 percent. No difference in the average number of adverse effects per patient was observed over the two observation periods. These findings were associated with an estimated $22,000/month cost savings. The consensus approach alone, without benefit of the clinical pharmacist, was not associated with improved therapeutic outcome or cost savings over the same observation periods. CONCLUSIONS: These data suggest that a consensus approach to antibiotic therapy can be cost-effective. An individual, such as a clinical pharmacist, may add significantly to quality improvement and cost-effective efforts in a hospital setting.


This article has been cited by other articles:


Home page
 Int J Qual Health CareHome page
K. E. Kilpatrick, K. N. Lohr, S. Leatherman, G. Pink, J. M. Buckel, C. Legarde, and L. Whitener
The insufficiency of evidence to establish the business case for quality
Int. J. Qual. Health Care, August 1, 2005; 17(4): 347 - 355.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
A. S. Pickard, L.-A. Topfer, and D. H. Feeny
A Structured Review of Studies on Health-Related Quality of Life and Economic Evaluation in Pediatric Acute Lymphoblastic Leukemia
J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 102 - 125.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
G. L. Fraser, P. Stogsdill, J. D. Dickens Jr, D. E. Wennberg, R. P. Smith Jr, and B. S. Prato
Antibiotic Optimization: An Evaluation of Patient Safety and Economic Outcomes
Arch Intern Med, August 11, 1997; 157(15): 1689 - 1694.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1994 by Harvey Whitney Books Company.